Thelansis

Distal Renal Tubular Acidosis (dRTA) Market Outlook Thelansis’s “Distal Renal Tubular Acidosis (dRTA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Distal Renal Tubular Acidosis (dRTA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

Distal Renal Tubular Acidosis (dRTA) Market Outlook Thelansis’s “Distal Renal Tubular Acidosis (dRTA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Distal Renal Tubular Acidosis (dRTA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Distal Renal Tubular Acidosis (dRTA) Overview Distal renal tubular acidosis (dRTA) or RTA type-I comprises a group of disorders in which the excretion of hydrogen ions or reabsorption of filtered HCO3 is impaired, resulting in chronic metabolic acidosis with a standard anion gap. In children affected by dRTA, there is stunted growth, loss of appetite, constipation, vomiting, nephrocalcinosis, pol...

  Distal renal tubular acidosis (dRTA) or RTA type-I comprises a group of disorders in which the excretion of hydrogen ions or reabsorption of filtered HCO3 is impaired, resulting in chronic metabolic acidosis with a standard anion gap. In children affected by dRTA, there is stunted growth, loss of appetite, constipation, vomiting, nephrocalcinosis, polydipsia and polyuria, weakness and muscle paralysis due to hypokalemia. DRTA can be autosomal dominant or autosomal recessive. Autosomal recessive dRTA manifests itself in the first months of life and progresses with nephrocalcinosis and early or late hearing loss. Autosomal dominant dRTA is less severe, occurs during adolescence or adulthood, and may or may not develop nephrocalcinosis. In alpha-intercalated cells of the collecting duct, the acid load is deposited into the urine as titratable acids (phosphates) and ammonium. Mutations in the genes ATP6V1B1, ATP6V0A4, and SLC4A1 cause autosomal recessive dRTA, which encode subunits...

 Distal renal tubular acidosis (dRTA) or RTA type-I comprises a group of disorders in which the excretion of hydrogen ions or reabsorption of filtered HCO3 is impaired, resulting in chronic metabolic acidosis with a standard anion gap. In children affected by dRTA, there is stunted growth, loss of appetite, constipation, vomiting, nephrocalcinosis, polydipsia and polyuria, weakness and muscle paralysis due to hypokalemia. DRTA can be autosomal dominant or autosomal recessive. Autosomal recessive dRTA manifests itself in the first months of life and progresses with nephrocalcinosis and early or late hearing loss. Autosomal dominant dRTA is less severe, occurs during adolescence or adulthood, and may or may not develop nephrocalcinosis. In alpha-intercalated cells of the collecting duct, the acid load is deposited into the urine as titratable acids (phosphates) and ammonium. Mutations in the genes ATP6V1B1, ATP6V0A4, and SLC4A1 cause autosomal recessive dRTA, which encode subunits a4...